147
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

, , ORCID Icon, , , , & ORCID Icon show all
Pages 213-225 | Published online: 22 Jun 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Toshko Lissitchkov, Anna Klukowska, Evgeny Buevich, Irina Maltceva, Guenter Auerswald, Oleksandra Stasyshyn, Wilfried Seifert & Tobias Rogosch. (2020) An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study). Journal of Blood Medicine 11, pages 345-356.
Read now

Articles from other publishers (3)

Lucia Rugeri, Annie Harroche, Yohan Repessé, Dominique Desprez, Brigitte Pan Petesch, Pierre Chamouni, Christine Biron, Birgit Frotscher, Hasan Catovic, Diane Bracquart, Cédric Martin, Marc Trossaërt, Sandrine Meunier & Roseline d'Oiron. (2022) Effectiveness of long‐term prophylaxis using pdFVIII / VWF concentrate in patients with inherited von Willebrand disease . European Journal of Haematology 109:1, pages 109-117.
Crossref
Wolfgang Miesbach & Erik Berntorp. (2021) Translating the success of prophylaxis in haemophilia to von Willebrand disease. Thrombosis Research 199, pages 67-74.
Crossref
Massimo Franchini, Omid Seidizadeh & Pier Mannuccio Mannucci. (2021) Prophylactic management of patients with von Willebrand disease. Therapeutic Advances in Hematology 12, pages 204062072110640.
Crossref